Close
Close

Novartis Pharmaceuticals - FLT3-mutated Acute Myeloid Leukemia

Partner

Not provided

Rare Disease

FLT3-mutated Acute Myeloid Leukemia

Sponsor

Novartis Pharmaceuticals

Access Program Information

The purpose of this study is to gather and evaluate additional safety data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy and are without satisfactory treatment alternatives prior to the commercial availability* and reimbursement of midostaurin during the regulatory approval process

Contact

Contact: Novartis Pharmaceuticals (+41613241111)

Locations
  • Canada

Free Newsletter